Leggi questo articolo ad alta voce
Attiva il microfono e leggi con il tuo ritmo. Le parole si illuminano mentre procedi, e nulla ti ferma quando una viene pronunciata male.
Il tuo audio non arriva mai a MovaReader: a riconoscerlo è il tuo browser. Informativa sulla privacy
Accedi per conservare questa sessione nella cronologia delle letture.
Assessing Off-Target Activity in Preclinical CRISPR Gene Editing
The therapeutic deployment of programmable endonucleases, particularly the CRISPR-Cas9 system derived from Streptococcus pyogenes, has revolutionized translational genetics, yet evaluating genomic precision requires rigorous epistemic caution. While standard assays demonstrate that guide RNAs direct the Cas9 endonuclease to cleave targeted loci adjacent to protospacer adjacent motifs, unintended double-strand breaks can occur at non-target sites displaying partial sequence homology. Preclinical evaluations often rely on cell-based selection assays such as GUIDE-seq or in vitro digestion methods like CIRCLE-seq to detect potential off-target cuts. However, molecular geneticists tend to emphasize that cell-free and immortalized cell-line models do not fully mirror chromatin accessibility within primary human tissues.
The biological consequences of off-target cleavage appear to depend heavily on cellular context and repair pathway dynamics. Non-homologous end